Pages that link to "Q34647097"
Jump to navigation
Jump to search
The following pages link to Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells (Q34647097):
Displaying 50 items.
- CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy (Q24678297) (← links)
- Linkers Having a Crucial Role in Antibody-Drug Conjugates (Q26752763) (← links)
- Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics (Q26780335) (← links)
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin (Q27009160) (← links)
- Antibody Drug Conjugates: Preclinical Considerations (Q27022321) (← links)
- Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation (Q28207989) (← links)
- SIGLEC12, a Human-specific Segregating (Pseudo)gene, Encodes a Signaling Molecule Expressed in Prostate Carcinomas (Q28237131) (← links)
- Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization (Q28476825) (← links)
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials (Q30835785) (← links)
- Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner (Q33195487) (← links)
- Obligate multivalent recognition of cell surface tomoregulin following selection from a multivalent phage antibody library (Q33263079) (← links)
- Leukemia-targeting ligands isolated from phage-display peptide libraries. (Q33270272) (← links)
- Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). (Q33343994) (← links)
- Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence (Q33368039) (← links)
- High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group (Q33373033) (← links)
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study (Q33400617) (← links)
- Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse (Q33412354) (← links)
- Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation (Q33418153) (← links)
- Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study (Q33558088) (← links)
- Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and [...] (Q33828797) (← links)
- Gemtuzumab ozogamicin (Q34340421) (← links)
- Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy (Q34973413) (← links)
- Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse (Q35007569) (← links)
- Minimising the long-term adverse effects of childhood leukaemia therapy (Q35009418) (← links)
- Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin (Q35029920) (← links)
- Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia (Q35034815) (← links)
- Prodrugs for improving tumor targetability and efficiency. (Q35095165) (← links)
- Mechanism of action and resistance to monoclonal antibody therapy (Q35206345) (← links)
- New developments in antibody therapy for acute myeloid leukemia (Q35206364) (← links)
- Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components (Q35459059) (← links)
- CD34( )/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin (Q35717808) (← links)
- Emerging treatments in acute myeloid leukaemia (Q35779278) (← links)
- Human leukaemic stem cells: a novel target of therapy. (Q35854964) (← links)
- On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. (Q35854970) (← links)
- Native antibody and antibody-targeted chemotherapy for acute myeloid leukemia (Q35909302) (← links)
- CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance (Q35980938) (← links)
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy (Q36058588) (← links)
- Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). (Q36158816) (← links)
- Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody (Q36214426) (← links)
- Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody (Q36216376) (← links)
- Recent advances in targeted therapy of human myelogenous leukaemia (Q36318531) (← links)
- The role of gemtuzumab ozogamicin in acute leukaemia therapy (Q36367816) (← links)
- In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer (Q36407249) (← links)
- Molecular target therapy for synovial sarcoma (Q36429636) (← links)
- Development of antibodies and chimeric molecules for cancer immunotherapy (Q36490753) (← links)
- Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts (Q36591404) (← links)
- Monoclonal antibody-based therapeutics for leukemia (Q36739759) (← links)
- Technology insight: cytotoxic drug immunoconjugates for cancer therapy (Q36773469) (← links)
- Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group (Q36805474) (← links)
- The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients (Q36832124) (← links)